Eyeing Solo U.S. Debut, EU Biotech ThromboGenics Preps Ocriplasmin For Launch
Executive Summary
Small European biotechs usually build their business in their home region first, and later look to the US for growth. Belgium's ThromboGenics is doing the opposite; it aims to launch its lead product initially in the US, and will tackle Europe after partner and market leader Alcon paves the way.
You may also be interested in...
ThromboGenics’ Jetrea Clears Advisory Panel, But Questions On Population Size Remain
FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted 10-0 that the risk-benefit ratio of ocriplasmin for vitreomacular adhesions is positive, and 6-3 that no additional pre-approval studies are needed.
ThromboGenics Ocriplasmin’s Advisory Panel Likely To Focus On Safety
ThromboGenics will seek to convince the Dermatologic and Ophthalmic Drugs Advisory Committee that further safety studies should not be made a condition of approval of its ocriplasmin for symptomatic vitreomacular adhesion, including macular hole.
Alcon Grabs Ex-U.S. Rights To ThromboGenics' Retina Adhesion Therapy Ocriplasmin In $500 Mil. Deal
Novartis' ophthalmic unit Alcon will collaborate with Belgium's ThromboGenics on the marketing and future development of the vitreomacular adhesion therapy, ocriplasmin.